Hormone replacement therapy use and plasma levels of sex hormones in the Norwegian Women and Cancer Postgenome Cohort : a cross-sectional analysis
Permanent lenke
https://hdl.handle.net/10037/1424DOI
doi:10.1186/1472-6874-8-1Dato
2008-02-14Type
Journal articleTidsskriftartikkel
Peer reviewed
Forfatter
Waaseth, Marit; Bakken, Kjersti; Dumeaux, Vanessa; Olsen, Karina Standahl; Rylander, Charlotta; Figenschaug, Yngve; Lund, EilivSammendrag
Background: Hormone replacement therapy use (HRT) is associated with increased breast cancer risk. Our
primary objective was to explore hormone levels in plasma according to HRT use, body mass index (BMI) and
menopausal status. A secondary objective was to validate self-reported questionnaire information on
menstruation and HRT use in the Norwegian Women and Cancer postgenome cohort (NOWAC).
Methods: We conducted a cross-sectional study of sex hormone levels among 445 women aged 48–62 who
answered an eight-page questionnaire in 2004 and agreed to donate a blood sample. The samples were drawn at
the women's local general physician's offices in the spring of 2005 and sent by mail to NOWAC, Tromsø, together
with a two-page questionnaire. Plasma levels of sex hormones and Sex Hormone Binding Globulin (SHBG) were
measured by immunometry. 20 samples were excluded, leaving 425 hormone measurements.
Results: 20% of postmenopausal women were HRT users. The plasma levels of estradiol (E2) increased with an
increased E2 dose, and use of systemic E2-containing HRT suppressed the level of Follicle Stimulating Hormone
(FSH). SHBG levels increased mainly among users of oral E2 preparations. Vaginal E2 application did not influence
hormone levels. There was no difference in BMI between HRT users and non-users. Increased BMI was associated
with increased E2 and decreased FSH and SHBG levels among non-users. Menopausal status defined by the twopage
questionnaire showed 92% sensitivity (95% CI 89–96%) and 73% specificity (95% CI 64–82%), while the eightpage
questionnaire showed 88% sensitivity (95% CI 84–92%) and 87% specificity (95% CI 80–94%). Current HRT
use showed 100% specificity and 88% of the HRT-users had plasma E2 levels above the 95% CI of non-users.
Conclusion: Users of systemic E2-containing HRT preparations have plasma E2 and FSH levels comparable to
premenopausal women. BMI has an influence on hormone levels among non-users. NOWAC questionnaires
provide valid information on current HRT use and menopausal status among Norwegian women who are
between 48 and 62 years old.
Beskrivelse
This paper is part of Marit Waaseth's ph.d. thesis which is available in Munin at http://hdl.handle.net/10037/2646
Forlag
BioMed CentralSitering
BMC Women's Health 8(2008) article no 1Metadata
Vis full innførselSamlinger
Følgende lisensfil er knyttet til denne innførselen: